



European Monitoring Centre
for Drugs and Drug Addiction

PROGRAMME

Drug-related infectious diseases (DRID)

2018 expert meeting

24–25 September 2018
EMCDDA, Lisbon

2018 expert meeting on drug-related infectious diseases (DRID)

Monday 24 September 2018	
09.00	<p>Introduction Thomas Seyler, EMCDDA</p>
09.15	<p>Session 1: Hepatitis B and C Barometer for PWID Chairs: Maria Axelsson, Sweden and Thomas Seyler, EMCDDA</p> <p>Objective: presenting the core indicators for the monitoring of the Health Sector Strategy on viral hepatitis among PWID</p> <p>Setting the scene — Antons Mozalevskis, WHO EU monitoring programme for Hepatitis — Erika Duffell, ECDC Hepatitis B and C Elimination Barometer for PWID — Thomas Seyler, EMCDDA</p> <p>Context and need (Epidemic pattern) New HCV/HBV prevalence data from Latvia — Anda Kīvīte, Latvia Using RNA biomarker for prevalence of chronic HCV in the UK — Katy Sinka, United Kingdom</p>
10.30	Coffee break
11.00	<p>Session 1: Hepatitis B and C Barometer for PWID (cont.) Chairs: Anna Tarján, Hungary and Thomas Seyler, EMCDDA</p> <p>Inputs (policy) Malta's National Strategy for the Elimination of Hepatitis C Virus — Christine Marchand-Agius, Malta</p> <p>Outputs and outcome (prevention and cascade of care) Prevention of HCB and HCV among PWID in the Czech Republic — Barbara Janikova, Czech Republic HCV testing of people in treatment for substance use disorders in Belgium between 2011 and 2014 — Luk Van Baelen, Belgium The cascade of HCV care in PWIDs from Luxembourg — Carole Devaux, Luxembourg</p> <p>Impact (incidence and mortality) Model projections to estimate the impact of HCV prevention and treatment interventions in Europe — Hannah Fraser, United Kingdom</p>
12.30	Lunch break
13.30	<p>Session 2: Infectious disease outbreaks among drug users Chairs: Erika Duffell, ECDC and Irene Schmutterer, Austria</p> <p>Objective: Providing an update on recent or current outbreaks among drug users</p> <p>Outbreak of HIV-1 subtype C infections among PWID in Bavaria, Germany — Ruth Zimmerman, Germany Group A Streptococcus and other bacterial infections among people who inject drugs in the UK — Katy Sinka, United Kingdom HIV in Glasgow — Vivian Hope, United Kingdom</p>

14.30	<p>Session 3: Cornerstone lab on European projects</p> <p>Chairs: Eleni Kalamara and Klaudia Palczak, EMCDDA</p> <p>Objective: Presenting European projects that EMCDDA is part of</p> <p>Sphere C — Ruth Zimmerman, Germany and Erika Duffell, ECDC</p> <p>Hep Care — Jack Lambert, Ireland</p> <p>HA-REACT WP4 — Alexandra Gurinova, Germany</p> <p>Trendspotter on cocaine — Alessandro Pirona, EMCDDA</p>
15.30	Coffee break
16.00	<p>Session 4: Testing for Hepatitis C</p> <p>Chair: Dagmar Hedrich, EMCDDA</p> <p>Objective: to hear about the role of testing as part of hepatitis elimination and share experiences from the Netherlands and France, and to provide an overview of the EMCDDA initiative to promote testing in drug treatment services</p> <p>Testing in drugs services</p> <p>HCV elimination among PWID in the Netherlands: The 5 steps of the national hepatitis plan — focus on case finding in drug treatment setting — Esther Croes, the Netherlands</p> <p>French experience on HCV testing and HCV treatment — Anne-Claire Brisacier, France</p> <p>Discussion</p>
16.30	<p>EMCDDA testing initiative</p> <p>EMCDDA initiative to promote HCV testing in treatment settings — Nicola Singleton, EMCDDA</p> <p>Diagnostic tool, Knowledge questionnaire — Ida Sperle-Heupel, EMCDDA consultant</p> <p>Experiences from pilot test knowledge questionnaire — Klaudia Palczak, EMCDDA</p> <p>Update on collection of best practice examples on testing in drug treatment services — Stine Nielsen, EMCDDA consultant</p> <p>Questions and clarification</p>
17.30	End of day one
19.30	Network dinner at Clube dos Jornalistas

Tuesday 25 September 2018	
09.00	<p>Session 5: Data session 1 — Quality criteria and “ranking” for DRID data</p> <p>Chairs: Eleni Kalamara, EMCDDA and Vivian Hope, United Kingdom</p> <p>Objective: Highlighting the importance of a quality scoring system and working on a scoring proposal</p> <p>DRID indicator: proposals to assess quality — Eleni Kalamara, EMCDDA and Vivian Hope, United Kingdom</p> <p>Feedback from Latvia, Belgium and Greece</p> <p>Discussion</p>
10.15	Coffee break
10.45	<p>Session 6: Behavioural data — why and how to improve completeness of the core data</p> <p>Chairs: Anastasios Fotiou, Greece and Isabelle Giraudon, EMCDDA</p> <p>Objective: Reviewing the DRID core behavioural data; discussing current bio-behavioural studies and reflecting on directions for work to improve the completeness and the utility of this data</p> <p>Current state of the DRID bio-behavioural data collection, and discussion on possible ways forward — Isabelle Giraudon, EMCDDA and Vivian Hope, United Kingdom</p> <p>Feedback from Germany, Slovakia, Hungary and France</p> <p>Discussion</p>
12.00	<p>Session 7: Drug-related infectious diseases in prison</p> <p>Chairs: Ioanna Yiasemi, Cyprus and Linda Montanari, EMCDDA</p> <p>Objective: Presenting studies and initiatives related to the prevention of drug-related infectious diseases in prisons</p> <p>HIV in prison in Lithuania — Ieva Vaitkevičiūtė, Lithuania</p> <p>All-inclusive HCV testing strategy in prison in Estonia</p> <p>Prison Guidance — Dagmar Hedrich, EMCDDA</p>
12.45	Conclusions
13.00	End of the meeting